Real-world data has become increasingly vital for pharmaceutical companies seeking answers to their commercial questions, with unstructured electronic medical record (EMR) data emerging as a crucial but often overlooked resource. This data type proves invaluable when companies need to identify specific patient
populations, conduct outcomes research, or generate evidence for their products.
Historically, analyzing unstructured EMR data at scale presented significant challenges. While structured EMR data – such as patient demographics and procedural records – follows standardized formats enabling straightforward analysis, the qualitative information documented by healthcare providers in free-text fields has remained largely inaccessible.
Consider a practical example: A grandmother receiving treatment for stage 3 breast cancer. While traditional data sources like medical claims provide basic information about her treatment path, the most valuable details about her condition – including tumor
characteristics, biomarker status, and physician observations – exist within unstructured clinical notes.
For pharmaceutical companies developing targeted therapies, accessing this detailed clinical information is essential. Without the ability to analyze unstructured data, manufacturers struggle to identify suitable patients, such as those with specific tumor sizes and biomarker profiles who could benefit from their treatments.
Recent advances in artificial intelligence and natural language processing have transformed this landscape. These technologies now enable pharmaceutical companies to systematically analyze unstructured clinical data, extracting key information about disease progression, family history, and physician assessments. This capability proves particularly valuable in oncology, where manufacturers can now identify patients based on specific genetic variants and expression levels – details often missing from structured data sources.
By combining structured and unstructured data analysis, pharmaceutical companies can significantly refine their patient identification processes. Rather than working with broad patient populations, they can precisely target individuals meeting specific clinical criteria and connect with their healthcare providers at crucial treatment decision points.
This integrated approach to data analysis serves multiple purposes beyond patient identification. Companies can develop customized analytics tools to track patient populations over time, enabling them to alert sales representatives when patients reach critical treatment milestones. The longitudinal nature of the data also supports comprehensive outcomes research, helping manufacturers demonstrate their products’ value compared to existing treatments.
The ability to analyze unstructured EMR data alongside other real-world data sources enables pharmaceutical companies to create detailed maps of patient journeys, identify treatment barriers, and improve therapy access. For instance, manufacturers can track patients from initial diagnosis through various treatment stages, using weekly updates to ensure timely interventions.
Companies can also leverage this comprehensive data to conduct historical outcomes analyses, developing compelling evidence for new treatments by examining results from existing therapies. Additionally, the data reveals patterns in physician behavior and unmet medical needs, potentially informing future drug development priorities.
The integration of unstructured EMR data with other healthcare information sources – including medical claims, laboratory results, and structured EMR data – creates a powerful tool for pharmaceutical companies. This combined dataset supports various commercial and research applications, from precise patient targeting to comprehensive outcomes studies. By extracting insights from previously inaccessible clinical information, companies can better understand patient needs and optimize treatment delivery, ultimately improving healthcare outcomes.
Be First to Comment